Stock 002940 ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Equities

002940

CNE100003GC2

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
17.37 CNY -1.86% Intraday chart for Zhejiang AngLiKang Pharmaceutical CO.,LTD. -5.34% -19.99%
26/04 Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02/04 Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
CI
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets
MT
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares.
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan.
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates
MT
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China
MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022
CI
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm
MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Zhejiang Anglikang Pharma to Boost Stake in Local Biopharma Firm to 62% For 191 Million Yuan
MT
Zhejiang AngLiKang Pharmaceutical CO.,LTD. completed the acquisition of an additional 38.22% stake in Hunan Kerey Pharmaceutical Co., Ltd. from Gan Hongxing, Hu Aiguo, Yang Xiangxin and Xie Laibin.
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. signed a share transfer agreement to acquire an additional 38.22% stake in Hunan Kerey Pharmaceutical Co., Ltd. from Gan Hongxing, Hu Aiguo, Yang Xiangxin and Xie Laibin for approximately CNY 191.3 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002940 Stock
  4. News Zhejiang AngLiKang Pharmaceutical CO.,LTD.
  5. Highlights